Vir’s dose response, safety data spur combo studies of Alnylam-partnered HBV therapy

With an eye towards a functional cure for chronic HBV, Vir plans to begin testing its siRNA therapy next half in combination with immune boosters. Phase I/II data unveiled Wednesday showed that VIR-2218 alone led to durable, dose-dependent reductions in HBsAG levels in the Phase

Read the full 455 word article

How to gain access

Continue reading with a
two-week free trial.